FAQ / STRAIGHT ANSWERS
PT-141, answered: 22 common questions about bremelanotide.
Definitions, mechanism, the approved indication, the off-label male research, dosing, and side effects — each answered directly and cited where it makes a quantitative claim.
What is PT-141 used for?
PT-141 (bremelanotide) is FDA-approved (2019) only for acquired, generalized HSDD — persistently low sexual desire causing distress — in premenopausal women, given as a 1.75 mg subcutaneous injection as needed [3][6]. Every other use, including in men and for erectile dysfunction, is off-label and not supported by the approval.
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 activates central melanocortin receptors — chiefly MC4R — in hypothalamic and limbic circuits tied to sexual desire [1]. That is unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle to affect blood flow. The mechanism is central motivation, not local circulation [1].
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide (a seven-amino-acid ring) analogue of alpha-MSH that acts as a melanocortin (MC3R/MC4R) receptor agonist [1]. It was first studied in sexual dysfunction and is now an FDA-approved drug for one specific indication [6].
What is PT-141 peptide?
The PT-141 peptide is a seven-amino-acid cyclic peptide whose ring structure, closed by a lactam bridge, improves stability over linear melanocortin peptides [1][6]. It is the same molecule approved as bremelanotide. Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH; molecular weight 1025.2 Da [6].
What does the PT-141 peptide do?
It activates central melanocortin receptors — chiefly MC4R — in brain circuits governing sexual desire and arousal [1]. That central action is the basis for its approved use in premenopausal women with HSDD and for its off-label sexual-function research in men [3][6]. It does not act on blood vessels.
Is PT-141 the same as bremelanotide?
Yes. "PT-141" is the original research code; "bremelanotide" is the international nonproprietary name (INN) of the approved drug [6]. They refer to the identical molecule (CAS 189691-06-3), approved under NDA 210557 in June 2019 [6].
What is bremelanotide?
Bremelanotide is the FDA-approved (2019) melanocortin receptor agonist for acquired, generalized HSDD in premenopausal women — the same compound studied as PT-141 [6]. It is given as a 1.75 mg subcutaneous injection, as needed, and is the drug tested in the two RECONNECT Phase 3 trials [3][6].
How does PT-141 work?
By stimulating MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, engaging dopaminergic pathways linked to sexual motivation, rather than acting on blood vessels [1]. Animal and fMRI data both support this central mechanism [1][5]. It is a brain-circuit drug, not a blood-flow drug.
What receptors does PT-141 act on?
Primarily the melanocortin 4 receptor (MC4R), with secondary MC3R activity [1]. Peripheral MC1R activation in skin is linked to hyperpigmentation with repeated dosing [6][12]. The central MC3R/MC4R action is what drives the sexual-function effect [1].
What is a melanocortin receptor agonist?
A molecule that activates melanocortin receptors (MC1R-MC5R), a family of G-protein-coupled receptors responding to peptides like alpha-MSH [1]. PT-141 targets the central MC3R/MC4R subtypes. An agonist switches a receptor on, as opposed to blocking it [1].
Does PT-141 increase testosterone?
No. PT-141 does not act through the HPG (hypothalamic-pituitary-gonadal) axis and does not directly raise testosterone [1]. Its effect is central, via melanocortin receptors in sexual-motivation circuits, not hormonal. This is a common misconception about how the molecule works.
What does PT-141 do for men?
In early-phase research, systemic PT-141 produced dose-dependent erectile activity in men, including some sildenafil non-responders [1][7]. This use is off-label and investigational, not approved [6]. The current development program studies it co-administered with a PDE-5 inhibitor [14].
Is PT-141 approved for men?
No. The 2019 FDA approval covers only premenopausal women with HSDD [6]. Male and erectile-dysfunction use is off-label, and the male/erectile evidence is early-phase and investigational, not established [1][7].
How is PT-141 different from PDE-5 inhibitors?
PT-141 acts centrally on MC4R neural circuits of sexual motivation; PDE-5 inhibitors act peripherally on penile blood flow [1]. The mechanisms are complementary, not interchangeable — early studies even co-administered the two to combine central and peripheral effects [9].
Does PT-141 nasal spray work?
Early intranasal studies in men showed a statistically significant erectile response above ~7 mg, with onset near 30 minutes [7]. But the intranasal route was discontinued for pharmacokinetic variability in favor of subcutaneous dosing; the approved product is a subcutaneous injection, not a spray [6][7].
Is PT-141 better than PDE-5 inhibitors for erectile dysfunction?
There is no approval or head-to-head basis to call it better. PT-141 is not approved for ED, and current development studies it co-administered with a PDE-5 inhibitor in non-responders rather than as a replacement [14]. The two act by different mechanisms [1].
Why is PT-141 being studied with a PDE-5 inhibitor?
Because the mechanisms are complementary: a central melanocortin agonist plus a peripheral PDE-5 inhibitor [1][9]. In June 2024 the developer announced a Phase 2 study (~50 patients) of bremelanotide co-administered with a PDE-5 inhibitor in non-responders [14]. That is a development-status announcement, not a peer-reviewed result.
What is the PT-141 dosage?
The approved label specifies 1.75 mg subcutaneously as needed, at least 45 minutes before activity, no more than one dose per 24 hours and no more than 8 per month [6]. This is reported as a label finding, not a recommendation for any individual.
How much PT-141 should I take?
This site does not recommend a dose for anyone. The studied and labeled dose is 1.75 mg subcutaneous as needed; dosing is a clinical decision, and "PT-141 research chemical" is laboratory material, not the approved drug [6]. The figures here are findings, not guidance.
How much PT-141 to inject?
Trials and the label used 1.75 mg subcutaneously; earlier dose-finding in women tested 0.75, 1.25, and 1.75 mg [3][6]. These are reported findings, not dosing guidance, and this site recommends no dose to any reader [6].
What is the PT-141 dosage for women?
For the approved HSDD indication in premenopausal women, the label dose is 1.75 mg subcutaneous as needed (maximum one dose per 24 hours, 8 per month) [6]. Stated here strictly as the approved-label finding [3][6].
How do you reconstitute PT-141?
The approved bremelanotide product is supplied as a ready-to-use subcutaneous autoinjector, not reconstituted [6]. Lyophilized "research chemical" powder is a non-approved laboratory material; this site gives no preparation protocol for human use and recommends no dose [6].